Due to the pivotal nature of Phase I clinical trials, the industry demands a partner who is experienced.

With our one-of-a-kind credentials, Midlands IRB provides clients with the assurance of an efficient, thorough, and quality review, thereby helping researchers to determine the safety profile of an experimental therapy is effective. Since our inception in 2001, we have reviewed more than 1,300 new protocols in Phase I research.

This experience in Phase I research is translated into our operations and communicated to our clients. We do this to ensure that our clients’ research is evaluated in accordance with the most current thinking and best practices in human research protection, thus reducing the regulatory, legal, and ethical risks inherent within a study.

As the industry and Phase I research becomes increasingly complex, we look forward to helping your organization to achieve – and sustain – greater success.